OBJECTIVES: To determine the activity and tolerability of 100-mg once-daily (QD) dasatinib in patients with metastatic castration-resistance prostate cancer (CRPC). Dasatinib, an oral Src family kinase inhibitor, has demonstrated both preclinical and clinical activity with twice-daily dosing in patients with metastatic CRPC. METHODS: Chemotherapy-naive men with metastatic CRPC and increasing prostate-specific antigen levels were treated with dasatinib 100 mg QD. The primary measurement was a composite lack of disease progression, according to the Prostate Cancer Working Group 2 criteria, determined every 12 weeks during the study. The other analyses included changes in the prostate-specific antigen level, bone lesions, soft tissue disease, and bone turnover markers (urine N-telopeptide and bone alkaline phosphatase). RESULTS: The present trial was designed before the publication of the recent Prostate Cancer Working Group 2 criteria; however, the analyses are presented to conform to the updated guidelines. A total of 48 patients received dasatinib. A lack of disease progression was observed in 21 patients (44%) at week 12 and in 8 (17%) at week 24. Urine N-telopeptide was reduced by ≥40% from baseline in 22 (51%) of 43 patients, and bone alkaline phosphatase was decreased in 26 (59%) of 44 patients. Dasatinib was well-tolerated, with only 6 patients (13%) with drug-related grade 3-4 adverse events and 3 (6%) with grade 3 adverse events. The most common treatment-related adverse events (≥20%) were fatigue, nausea, diarrhea, headache, and anorexia. CONCLUSIONS: Dasatinib 100 mg QD has a favorable safety profile and maintains a similar degree of activity as the previously reported twice-daily dosing schedules. These data support additional study of dasatinib 100 mg QD for metastatic CRPC.
OBJECTIVES: To determine the activity and tolerability of 100-mg once-daily (QD) dasatinib in patients with metastatic castration-resistance prostate cancer (CRPC). Dasatinib, an oral Src family kinase inhibitor, has demonstrated both preclinical and clinical activity with twice-daily dosing in patients with metastatic CRPC. METHODS: Chemotherapy-naive men with metastatic CRPC and increasing prostate-specific antigen levels were treated with dasatinib 100 mg QD. The primary measurement was a composite lack of disease progression, according to the Prostate Cancer Working Group 2 criteria, determined every 12 weeks during the study. The other analyses included changes in the prostate-specific antigen level, bone lesions, soft tissue disease, and bone turnover markers (urine N-telopeptide and bone alkaline phosphatase). RESULTS: The present trial was designed before the publication of the recent Prostate Cancer Working Group 2 criteria; however, the analyses are presented to conform to the updated guidelines. A total of 48 patients received dasatinib. A lack of disease progression was observed in 21 patients (44%) at week 12 and in 8 (17%) at week 24. Urine N-telopeptide was reduced by ≥40% from baseline in 22 (51%) of 43 patients, and bone alkaline phosphatase was decreased in 26 (59%) of 44 patients. Dasatinib was well-tolerated, with only 6 patients (13%) with drug-related grade 3-4 adverse events and 3 (6%) with grade 3 adverse events. The most common treatment-related adverse events (≥20%) were fatigue, nausea, diarrhea, headache, and anorexia. CONCLUSIONS:Dasatinib 100 mg QD has a favorable safety profile and maintains a similar degree of activity as the previously reported twice-daily dosing schedules. These data support additional study of dasatinib 100 mg QD for metastatic CRPC.
Authors: A Lipton; L Demers; E Curley; V Chinchilli; L Gaydos; G Hortobagyi; R Theriault; D Clemens; L Costa; J Seaman; R Knight Journal: Eur J Cancer Date: 1998-12 Impact factor: 9.162
Authors: Robert E Coleman; Pierre Major; Allan Lipton; Janet E Brown; Ker-Ai Lee; Matthew Smith; Fred Saad; Ming Zheng; Yong Jiang Hei; John Seaman; Richard Cook Journal: J Clin Oncol Date: 2005-06-27 Impact factor: 44.544
Authors: Sangkil Nam; Donghwa Kim; Jin Q Cheng; Shumin Zhang; Ji-Hyun Lee; Ralf Buettner; Janni Mirosevich; Francis Y Lee; Richard Jove Journal: Cancer Res Date: 2005-10-15 Impact factor: 12.701
Authors: Serk In Park; Jing Zhang; Kacy A Phillips; John C Araujo; Amer M Najjar; Andrei Y Volgin; Juri G Gelovani; Sun-Jin Kim; Zhengxin Wang; Gary E Gallick Journal: Cancer Res Date: 2008-05-01 Impact factor: 12.701
Authors: Howard I Scher; Susan Halabi; Ian Tannock; Michael Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia Higano; Glenn J Bubley; Robert Dreicer; Daniel Petrylak; Philip Kantoff; Ethan Basch; William Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain Journal: J Clin Oncol Date: 2008-03-01 Impact factor: 44.544
Authors: Dominik R Berthold; Gregory R Pond; Freidele Soban; Ronald de Wit; Mario Eisenberger; Ian F Tannock Journal: J Clin Oncol Date: 2008-01-10 Impact factor: 44.544
Authors: Venita DePuy; Kevin J Anstrom; Liana D Castel; Kevin A Schulman; Kevin P Weinfurt; Fred Saad Journal: Support Care Cancer Date: 2007-07 Impact factor: 3.359
Authors: Evan Y Yu; Fenghai Duan; Mark Muzi; Xuan Deng; Bennett B Chin; Joshi J Alumkal; Mary-Ellen Taplin; Jina M Taub; Ben Herman; Celestia S Higano; Robert K Doot; Donna Hartfeil; Philip G Febbo; David A Mankoff Journal: J Nucl Med Date: 2015-01-29 Impact factor: 10.057
Authors: Andreas Varkaris; Anastasia D Katsiampoura; John C Araujo; Gary E Gallick; Paul G Corn Journal: Cancer Metastasis Rev Date: 2014-09 Impact factor: 9.264
Authors: Adam T Szafran; Cliff Stephan; Michael Bolt; Maureen G Mancini; Marco Marcelli; Michael A Mancini Journal: Prostate Date: 2016-10-04 Impact factor: 4.104
Authors: Daniela Hoehn; Jorge E Cortes; L Jeffrey Medeiros; Elias J Jabbour; Juliana E Hidalgo; Rashmi Kanagal-Shamanna; Carlos E Bueso-Ramos Journal: Clin Lymphoma Myeloma Leuk Date: 2016-08